Generate Chart For |
|
|
(Chart displayed below) |
Rat Strains
{{sample.term}}
|
Measurement Methods
{{method.term}}
|
|
|
48 | mammary tumor number | SPRD/Ztm | female | 11.23 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 11340 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
46 | mammary tumor number | SPRD.WKY-(D18Wox8-D18Rat44)/Ibmm | female | 7.61 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 11342 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
14 | mammary tumor number | SPRD.WKY-(D5Rat190-D5Rat114)/Ibmm | female | 3.93 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 11341 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
7 | mammary tumor number | COP/CrCrl | female | 0.1 | | 17 beta-estradiol (27.5 mg) (for 196 days) | 11370 | 17 beta-estradiol (27.5 mg) (for 196 days) | | | | | | | |
5 | mammary tumor number | COP/CrCrl | female | 0 | | control condition | 11369 | control condition | | | | | | | |
21 | mammary tumor number | ACI/SegHsd | female | 7 | | 17 beta-estradiol (27.5 mg) (for 196 days) | 11368 | 17 beta-estradiol (27.5 mg) (for 196 days) | | | | | | | |
4 | mammary tumor number | ACI/SegHsd | female | 0 | | control condition | 11367 | control condition | | | | | | | |
12 | mammary tumor number | ACI.COP-(D10Mgh8-D10Rat4)/Shul | female | 4.8 | | 17 beta-estradiol (27.5 mg) (for 196 days) | 11366 | 17 beta-estradiol (27.5 mg) (for 196 days) | | | | | | | |
3 | mammary tumor number | ACI.COP-(D10Mgh8-D10Rat4)/Shul | female | 0 | | control condition | 11365 | control condition | | | | | | | |
17 | mammary tumor number | ACI.COP-(D3Rat130-D3Rat114)/Shul | female | 4.5 | | 17 beta-estradiol (27.5 mg) (for 196 days) | 11364 | 17 beta-estradiol (27.5 mg) (for 196 days) | | | | | | | |
3 | mammary tumor number | ACI.COP-(D3Rat130-D3Rat114)/Shul | female | 0 | | control condition | 11363 | control condition | | | | | | | |
8 | mammary tumor number | ACI.COP-(D3Mgh16-D3Rat119)/Shul | female | 4.3 | | 17 beta-estradiol (27.5 mg) (for 196 days) | 11362 | 17 beta-estradiol (27.5 mg) (for 196 days) | | | | | | | |
3 | mammary tumor number | ACI.COP-(D3Mgh16-D3Rat119)/Shul | female | 0 | | control condition | 11361 | control condition | | | | | | | |
17 | mammary tumor number | ACI.COP-(D6Rat80-D6Rat146)/Shul | female | 2.4 | | 17 beta-estradiol (27.5 mg) (for 196 days) | 11360 | 17 beta-estradiol (27.5 mg) (for 196 days) | | | | | | | |
3 | mammary tumor number | ACI.COP-(D6Rat80-D6Rat146)/Shul | female | 0 | | control condition | 11359 | control condition | | | | | | | |
20 | mammary tumor number | ACI/SegHsd | female | 5.6 | | 17 beta-estradiol (27.5 mg) (between 99 and 197 days) | 11377 | 17 beta-estradiol (27.5 mg) (between 99 and 197 days) | | | | | | | |
14 | mammary tumor number | SS-Chr 19BN/Mcwi | female | 8.79 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 11507 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
13 | mammary tumor number | SS-Chr 16BN/Mcwi | female | 6.31 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 11504 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
13 | mammary tumor number | SS-Chr 13BN/Mcwi | female | 5.33 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 11501 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
40 | mammary tumor number | SS/JrHsdMcwi | female | 2.45 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 11488 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
14 | mammary tumor number | SS.BN-(D13Hmgc64-RN34_13048990782)/Mcwi | female | 4.86 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 65573 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
14 | ratio of deaths related to DMBA toxicity to total study population during a period of time | SS.BN-(D6Rat149-D6Arb3)/Mcwi | female | 57 | % | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 65575 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
15 | ratio of deaths related to DMBA toxicity to total study population during a period of time | SS.BN-(D6Rat149-D6Rat18)/Mcwi | female | 80 | % | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 65576 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
15 | ratio of deaths related to DMBA toxicity to total study population during a period of time | SS.BN-(D6Rat149-D6Got171)/Mcwi | female | 40 | % | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 65577 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
20 | ratio of deaths related to DMBA toxicity to total study population during a period of time | SS-Chr 6BN/Mcwi | female | 95 | % | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 65578 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
14 | mammary tumor number | SS.BN-(D6Rat149-D6Arb3)/Mcwi | female | 4.77 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | 65571 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days) | | | | | | | |
17 | mammary tumor number | WKY/NHsd | female | 0 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 11741 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
21 | mammary tumor number | WF/NHsd | female | 7.3 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 11742 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
30 | mammary tumor number | WF/NHsd | female | 8.1 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 11746 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
16 | mammary tumor number | COP/OlaHsd | female | 0.25 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 11747 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
29 | mammary tumor number | WF/NHsd | female | 6.3 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 70167 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
19 | mammary tumor number | WF.COP-(D2Mit29-D2Rat201)/Uwm | female | 1.5 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | 70168 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) | | | | | | | |
8 | percentage of study population developing unilateral renal agenesis during a period of time | F344/Jcl | male | 0 | % | control condition | 106884 | control condition | | | | | | | |
8 | percentage of study population developing subcutaneous tumors during a period of time | F344/Jcl | male | 38 | % | control condition | 106886 | control condition | | | | | | | |
12 | percentage of study population developing subcutaneous tumors during a period of time | ACI/SegHsd | male | 0 | % | control condition | 106887 | control condition | | | | | | | |
12 | percentage of study population developing unilateral renal agenesis during a period of time | ACI/SegHsd | male | 24 | % | control condition | 106885 | control condition | | | | | | | |
53 | mammary tumor number | WF | female | 3.62 | | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (between 126 and 140 days) | 66100 | 7,12-dimethyltetraphene (DMBA) (65 mg/kg) (between 126 and 140 days) | | | | | | | |
8 | age at time of death | SS/Jr | not specified | 108 | d | controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 66 and 68 days) | 69608 | controlled sodium content diet (0.3 %) (between 10 and 12 days) | | controlled sodium content diet (2 %) (between 66 and 68 days) | | | | | |
8 | age at time of death | SS.SHR-(D9Mco72-D9Mco105)/Mco | not specified | 146 | d | controlled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 104 and 106 days) | 69610 | controlled sodium content diet (0.3 %) (between 10 and 12 days) | | controlled sodium content diet (2 %) (between 104 and 106 days) | | | | | |
20 | ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time | DA/ZtmKini | both | 0 | % | myelin oligodendrocyte glycoprotein (20 ug/200 ul) | 68125 | myelin oligodendrocyte glycoprotein (20 ug/200 ul) | | | | | | | |
19 | ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time | DA.PVG.1AV1-(D4Got126-D4Got136) | both | 0 | % | myelin oligodendrocyte glycoprotein (20 ug/200 ul) | 68127 | myelin oligodendrocyte glycoprotein (20 ug/200 ul) | | | | | | | |
23 | ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time | DA/ZtmKini | both | 61 | % | myelin oligodendrocyte glycoprotein (20 ug/200 ul) | 68129 | myelin oligodendrocyte glycoprotein (20 ug/200 ul) | | | | | | | |
21 | ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of time | DA.PVG.1AV1-(D4Got126-D4Got136) | both | 24 | % | myelin oligodendrocyte glycoprotein (20 ug/200 ul) | 68131 | myelin oligodendrocyte glycoprotein (20 ug/200 ul) | | | | | | | |
11 | percentage of study population developing liver tumors during a period of time | F344/NRrrc | not specified | 100 | % | controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days) | 68164 | controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days) | | | | | | | |
5 | percentage of study population developing liver tumors during a period of time | DRH/Seac | not specified | 0 | % | controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days) | 68165 | controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days) | | | | | | | |
9 | percentage of study population developing hepatocellular carcinoma during a period of time | F344/NHsd | not specified | 89 | % | N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 490 days) then partial hepatectomy | 96757 | N-nitrosodiethylamine (150 mg/kg) | | 2-acetamidofluorene (0.02 %) (for 490 days) | | | partial hepatectomy | | |
10 | percentage of study population developing hepatocellular carcinoma during a period of time | BN/SsNHsd | not specified | 10 | % | N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 490 days) then partial hepatectomy | 96758 | N-nitrosodiethylamine (150 mg/kg) | | 2-acetamidofluorene (0.02 %) (for 490 days) | | | partial hepatectomy | | |
96 | percentage of study population developing unilateral renal agenesis during a period of time | ACI/SegHsd | female | 13.5 | % | control condition | 69372 | control condition | | | | | | | |
36 | percentage of study population developing unilateral renal agenesis during a period of time | BN/SsNHsd | female | 0 | % | control condition | 69373 | control condition | | | | | | | |
87 | percentage of study population developing unilateral renal agenesis during a period of time | ACI/SegHsd | male | 5.7 | % | control condition | 69374 | control condition | | | | | | | |
43 | percentage of study population developing unilateral renal agenesis during a period of time | BN/SsNHsd | male | 0 | % | control condition | 69375 | control condition | | | | | | | |
20 | squamous cell carcinoma of the tongue tumor number | WF/Kga | both | 1 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70315 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
23 | squamous cell carcinoma of the tongue tumor number | WF.DA-(D19Mit1-D19Mit6)/Kop | both | 1.65 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70316 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
20 | squamous cell carcinoma of the tongue tumor number | DA/Slc | both | 2.35 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70317 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
20 | number of squamous cell tumors of the tongue with diameter greater than 3 mm | WF/Kga | both | 0.35 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70318 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
23 | number of squamous cell tumors of the tongue with diameter greater than 3 mm | WF.DA-(D19Mit1-D19Mit6)/Kop | both | 0.78 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70319 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
20 | number of squamous cell tumors of the tongue with diameter greater than 3 mm | DA/Slc | both | 1.6 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70320 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
20 | squamous cell carcinoma of the tongue maximum tumor diameter | WF/Kga | both | 1.15 | mm | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70321 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
23 | squamous cell carcinoma of the tongue maximum tumor diameter | WF.DA-(D19Mit1-D19Mit6)/Kop | both | 3.17 | mm | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70322 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
20 | squamous cell carcinoma of the tongue maximum tumor diameter | DA/Slc | both | 10.35 | mm | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70323 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
20 | squamous cell carcinoma of the head and neck tumor number | WF/Kga | both | 2.75 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70324 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
23 | squamous cell carcinoma of the head and neck tumor number | WF.DA-(D19Mit1-D19Mit6)/Kop | both | 4.75 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70325 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
20 | squamous cell carcinoma of the head and neck tumor number | DA/Slc | both | 5.55 | | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | 70326 | controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days) | | | | | | | |
47 | number of squamous cell tumors of the tongue with diameter greater than 5 mm | DA/Slc | both | 1.17 | | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70393 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
50 | number of squamous cell tumors of the tongue with diameter greater than 5 mm | WF | both | 0.04 | | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70394 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
47 | squamous cell carcinoma of the tongue tumor number | DA/Slc | both | 1.49 | | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70395 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
50 | squamous cell carcinoma of the tongue tumor number | WF | both | 0.42 | | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70396 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
47 | squamous cell carcinoma of the tongue maximum tumor diameter | DA/Slc | both | 12.77 | mm | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70397 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
50 | squamous cell carcinoma of the tongue maximum tumor diameter | WF | both | 1.18 | mm | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70398 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
47 | non-tongue squamous cell carcinoma of the head and neck tumor number | DA/Slc | both | 1.83 | | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70399 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
50 | non-tongue squamous cell carcinoma of the head and neck tumor number | WF | both | 0.78 | | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70400 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
47 | squamous cell carcinoma of the head and neck tumor number | DA/Slc | both | 3.34 | | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70401 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
50 | squamous cell carcinoma of the head and neck tumor number | WF | both | 1.26 | | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | 70402 | controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours) | | | | | | | |
22 | percentage of study population developing stomach tumors during a period of time | BUF/NacJcl | not specified | 14 | % | controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days) | 84752 | controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days) | | | | | | | |
21 | percentage of study population developing stomach tumors during a period of time | ACI/NJcl | not specified | 76 | % | controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days) | 84753 | controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days) | | | | | | | |
57 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX/Zte | male | 55 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98097 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
77 | post-insult time of death | BDIX.BDIV-D10Got1-D10Rat45/Zte | both | 239 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98176 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
109 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX/Zte | female | 49 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98177 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
75 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX.BDIV-D10Mit3-D10Mgh16/Zte | female | 7.9 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98178 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
77 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX.BDIV-D10Got1-D10Rat45/Zte | female | 22.5 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98179 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
57 | post-insult time of death | BDIX/Zte | male | 197 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98091 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
52 | post-insult time of death | BDIX/Zte | female | 214 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98092 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
38 | post-insult time of death | BDIX.BDIV-D10Mit3-D10Mgh16/Zte | male | 241 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98093 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
37 | post-insult time of death | BDIX.BDIV-D10Mit3-D10Mgh16/Zte | female | 272 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98094 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
37 | post-insult time of death | BDIX.BDIV-D10Got1-D10Rat45/Zte | male | 229 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98095 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
40 | post-insult time of death | BDIX.BDIV-D10Got1-D10Rat45/Zte | female | 348 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98096 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
52 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX/Zte | female | 41.5 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98098 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
38 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX.BDIV-D10Mit3-D10Mgh16/Zte | male | 13.9 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98099 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
37 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX.BDIV-D10Mit3-D10Mgh16/Zte | female | 2.9 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98100 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
37 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX.BDIV-D10Got1-D10Rat45/Zte | male | 32.7 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98101 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
40 | percentage of study population displaying trigeminal nerve neurilemmomas at a point in time | BDIX.BDIV-D10Got1-D10Rat45/Zte | female | 17.2 | % | N-ethyl-N-nitrosourea (80 ug/g) | 98102 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
109 | post-insult time of death | BDIX/Zte | both | 201 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98174 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
75 | post-insult time of death | BDIX.BDIV-D10Mit3-D10Mgh16/Zte | both | 247 | d | N-ethyl-N-nitrosourea (80 ug/g) | 98175 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
100 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Mit1-D6Mgh2/Zte | both | 234 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98130 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
57 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX | male | 197 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98125 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
52 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX | female | 214 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98126 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
109 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX | both | 201 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98127 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
51 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Mit1-D6Mgh2/Zte | male | 224 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98128 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
49 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Mit1-D6Mgh2/Zte | female | 279 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98129 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
39 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Rat132-D6Mgh3/Zte | male | 231 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98131 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
47 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Rat132-D6Mgh3/Zte | female | 235 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98132 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
86 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Rat132-D6Mgh3/Zte | both | 232 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98133 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
24 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Rat132-D6Rat229/Zte | both | 227 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98135 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
56 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Mit8-D6Rat229/Zte | male | 222 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98136 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
62 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Mit8-D6Rat229/Zte | female | 236 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98137 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
118 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIX.BDIV-D6Mit8-D6Rat229/Zte | both | 228 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98138 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
63 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIV | male | 593 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98139 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
49 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIV | female | 482 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98140 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
112 | post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumors | BDIV | both | 593 | d | N-ethyl-N-nitrosourea (80 mg/kg) | 98141 | N-ethyl-N-nitrosourea (80 mg/kg) | | | | | | | |
15 | post-insult time of death | BDIX/OrlCrl | male | 82.7 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) | 111117 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | | | | | |
14 | post-insult time of death | BDIX/OrlCrl | male | 77.4 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) | 111118 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | | | | | |
15 | post-insult time of death | BDIX/OrlCrl | male | 83.1 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then interleukin-2 (75000 U/d) (for 4 days) | 111119 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | interleukin-2 (75000 U/d) (for 4 days) | | | | | |
15 | post-insult time of death | BDIX/OrlCrl | male | 94 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) | 111120 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | interleukin-2 (75000 U/d) (for 4 days) | | | | |
15 | post-insult time of death | BDIX/OrlCrl | male | 81.7 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) | 111121 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | | | | |
16 | post-insult time of death | BDIX/OrlCrl | male | 80.5 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days) | 111142 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | sodium chloride solution (2 ml) (for 7 days) | | | sodium chloride solution (2 ml) (for 7 days) | | |
18 | post-insult time of death | BDIX/OrlCrl | male | 99.7 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) | 111143 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | | | 5-fluorouracil (100 mg/kg) (for 7 days) | | |
18 | post-insult time of death | BDIX/OrlCrl | male | 101.3 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) | 111144 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | interleukin-2 (75000 U/d) (for 4 days) | | 5-fluorouracil (100 mg/kg) (for 7 days) | interleukin-2 (75000 U/d) (for 4 days) | |
21 | post-insult time of death | BDIX/OrlCrl | male | 122.6 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) | 111145 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) |
13 | percentage of study population developing ascites during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) | 111124 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | sodium chloride solution (2 ml) (for 7 days) | | | | | |
16 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) and splenectomy then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days) | 111154 | DHD/K12/TRb cells (9 X 10E6) | splenectomy | sodium chloride solution (2 ml) (for 7 days) | | | sodium chloride solution (2 ml) (for 7 days) | | |
18 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 89 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) | 111155 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | | | 5-fluorouracil (100 mg/kg) (for 7 days) | | |
18 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 22 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) | 111156 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | interleukin-2 (75000 U/d) (for 4 days) | | 5-fluorouracil (100 mg/kg) (for 7 days) | interleukin-2 (75000 U/d) (for 4 days) | |
21 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 9.5 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) | 111157 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) |
13 | post-insult time of death | BDIX/OrlCrl | male | 78.5 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) | 111116 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | sodium chloride solution (2 ml) (for 7 days) | | | | | |
14 | post-insult time of death | BDIX/OrlCrl | male | 84 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) | 111122 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) | | | | |
15 | post-insult time of death | BDIX/OrlCrl | male | 98.7 | d | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) | 111123 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) | | | |
15 | percentage of study population developing ascites during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) | 111125 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | | | | | |
14 | percentage of study population developing ascites during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) | 111126 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | | | | | |
15 | percentage of study population developing ascites during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then interleukin-2 (75000 U/d) (for 4 days) | 111127 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | interleukin-2 (75000 U/d) (for 4 days) | | | | | |
15 | percentage of study population developing ascites during a period of time | BDIX/OrlCrl | male | 53 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) | 111128 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | interleukin-2 (75000 U/d) (for 4 days) | | | | |
15 | percentage of study population developing ascites during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) | 111129 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | | | | |
14 | percentage of study population developing ascites during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) | 111130 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) | | | | |
15 | percentage of study population developing ascites during a period of time | BDIX/OrlCrl | male | 13 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) | 111131 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) | | | |
13 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) | 111132 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | sodium chloride solution (2 ml) (for 7 days) | | | | | |
15 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 93 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) | 111133 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | | | | | |
14 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) | 111134 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | | | | | |
15 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 93 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then interleukin-2 (75000 U/d) (for 4 days) | 111135 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | interleukin-2 (75000 U/d) (for 4 days) | | | | | |
15 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 53 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) | 111136 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | interleukin-2 (75000 U/d) (for 4 days) | | | | |
15 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 87 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) | 111137 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | | | | |
14 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 100 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) | 111138 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) | | | | |
15 | percentage of study population developing extra-hepatic metastases during a period of time | BDIX/OrlCrl | male | 13 | % | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) | 111139 | DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) | splenectomy (for 0.1 hours) | 5-fluorouracil (100 mg/kg) (for 7 days) | Thymosin alpha-1 (200 ug/kg) (for 4 days) | interleukin-2 (75000 U/d) (for 4 days) | | | |
49 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIX.BDIV-D6Mit1-D6Mgh2/Zte | female | 9.6 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111211 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
20 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIX/Ifz | female | 43.9 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111208 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
32 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIV/lfz | female | 0 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111214 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
37 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIX/Ifz | both | 58 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111206 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
17 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIX/Ifz | male | 72.9 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111207 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
100 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIX.BDIV-D6Mit1-D6Mgh2/Zte | both | 23.8 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111209 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
51 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIX.BDIV-D6Mit1-D6Mgh2/Zte | male | 38.2 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111210 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
77 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIV/lfz | both | 0 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111212 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
45 | percentage of study population developing trigeminal nerve neurilemmomas during a period of time | BDIV/lfz | male | 0 | % | N-ethyl-N-nitrosourea (80 ug/g) | 111213 | N-ethyl-N-nitrosourea (80 ug/g) | | | | | | | |
9 | post-treatment survival time from doxorubicin-treated IgM immunocytoma | LOU/MWsl | male | 8 | d | rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then 0.9% sodium chloride solution | 109572 | rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) | | 0.9% sodium chloride solution | | | | | |
10 | post-treatment survival time from doxorubicin-treated IgM immunocytoma | LOU/MWsl | male | 23 | d | rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then doxorubicin (2 mg/kg) | 109573 | rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) | | doxorubicin (2 mg/kg) | | | | | |
10 | post-treatment survival time from doxorubicin-treated IgM immunocytoma | LOU/MWsl | male | 40 | d | rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then negatively charged liposome-entrapped doxorubicin (2 mg/kg) | 109574 | rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) | | negatively charged liposome-entrapped doxorubicin (2 mg/kg) | | | | | |
4 | ratio of deaths related to FUDR toxicity to total study population during a period of time | BDIX/HanHsd | female | 0 | % | DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours) | 111379 | DHD/K12/TRb - Sp-5 cells (1 X 10E6) | | isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours) | | | | | |
7 | ratio of deaths related to FUDR toxicity to total study population during a period of time | BDIX/HanHsd | female | 14 | % | DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours) | 111381 | DHD/K12/TRb - Sp-5 cells (1 X 10E6) | | isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours) | | | | | |
5 | ratio of deaths related to FUDR toxicity to total study population during a period of time | BDIX/HanHsd | female | 20 | % | DHD/K12/TRb - Sp-5 cells (1 X 10E6) then floxuridine (1 mg/kg/d) (for 7 days) | 111378 | DHD/K12/TRb - Sp-5 cells (1 X 10E6) | | floxuridine (1 mg/kg/d) (for 7 days) | | | | | |
5 | ratio of deaths related to FUDR toxicity to total study population during a period of time | BDIX/HanHsd | female | 0 | % | DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours) | 111380 | DHD/K12/TRb - Sp-5 cells (1 X 10E6) | | isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours) | | | | | |
7 | ratio of deaths related to FUDR toxicity to total study population during a period of time | BDIX/HanHsd | female | 14 | % | DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours) | 111382 | DHD/K12/TRb - Sp-5 cells (1 X 10E6) | | isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours) | | | | | |
3 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 0 | % | phosphate buffered saline (0.2 ml) then phosphate buffered saline (0.1 ml) | 111027 | phosphate buffered saline (0.2 ml) | | phosphate buffered saline (0.1 ml) | | | | | |
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 0 | % | DHD/K12/TRb cells (1 X 10E6) | 111028 | DHD/K12/TRb cells (1 X 10E6) | | | | | | | |
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 40 | % | DHD/K12/TRb cells (2 X 10E6) | 111029 | DHD/K12/TRb cells (2 X 10E6) | | | | | | | |
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 80 | % | DHD/K12/TRb cells (3 X 10E6) | 111030 | DHD/K12/TRb cells (3 X 10E6) | | | | | | | |
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 0 | % | DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) | 111031 | DHD/K12/TRb cells (1 X 10E6) | DHD/K12/TRb cells (0.5 X 10E6) | | | | | | |
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 0 | % | DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) | 111032 | DHD/K12/TRb cells (1 X 10E6) | DHD/K12/TRb cells (1 X 10E6) | | | | | | |
5 | percentage of study population developing peritoneal carcinomatosis during a period of time | BDIX/OrlCrl | male | 40 | % | DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) | 111033 | DHD/K12/TRb cells (1 X 10E6) | DHD/K12/TRb cells (1.5 X 10E6) | | | | | | |
16 | number of fetuses with visceral malformations to total number of fetuses ratio | WM/Nem | both | 33.3 | % | trypan blue (40 mg/kg) | 111288 | trypan blue (40 mg/kg) | | | | | | | |
28 | number of fetuses with visceral malformations to total number of fetuses ratio | WM/Nem | both | 25.7 | % | trypan blue (60 mg/kg) | 111289 | trypan blue (60 mg/kg) | | | | | | | |
21 | number of fetuses with visceral malformations to total number of fetuses ratio | WM/Nem | both | 31.5 | % | trypan blue (120 mg/kg) | 111290 | trypan blue (120 mg/kg) | | | | | | | |
51 | number of fetuses with visceral malformations to total number of fetuses ratio | BDIX/Nem | both | 6.4 | % | trypan blue (0 mg/kg) | 111291 | trypan blue (0 mg/kg) | | | | | | | |
60 | number of fetuses with visceral malformations to total number of fetuses ratio | BDIX/Nem | both | 2.8 | % | trypan blue (60 mg/kg) | 111292 | trypan blue (60 mg/kg) | | | | | | | |
32 | number of fetuses with visceral malformations to total number of fetuses ratio | BDIX/Nem | both | 19.2 | % | trypan blue (120 mg/kg) | 111293 | trypan blue (120 mg/kg) | | | | | | | |
43 | number of fetuses with hydrocephaly to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111294 | trypan blue (0 mg/kg) | | | | | | | |
16 | number of fetuses with hydrocephaly to total number of fetuses ratio | WM/Nem | both | 4.2 | % | trypan blue (40 mg/kg) | 111295 | trypan blue (40 mg/kg) | | | | | | | |
28 | number of fetuses with hydrocephaly to total number of fetuses ratio | WM/Nem | both | 6.5 | % | trypan blue (60 mg/kg) | 111296 | trypan blue (60 mg/kg) | | | | | | | |
21 | number of fetuses with hydrocephaly to total number of fetuses ratio | WM/Nem | both | 14.8 | % | trypan blue (120 mg/kg) | 111297 | trypan blue (120 mg/kg) | | | | | | | |
51 | number of fetuses with hydrocephaly to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111298 | trypan blue (0 mg/kg) | | | | | | | |
60 | number of fetuses with hydrocephaly to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111299 | trypan blue (60 mg/kg) | | | | | | | |
32 | number of fetuses with hydrocephaly to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (120 mg/kg) | 111300 | trypan blue (120 mg/kg) | | | | | | | |
43 | number of fetuses with cardiovascular malformations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111301 | trypan blue (0 mg/kg) | | | | | | | |
16 | number of fetuses with cardiovascular malformations to total number of fetuses ratio | WM/Nem | both | 29.1 | % | trypan blue (40 mg/kg) | 111302 | trypan blue (40 mg/kg) | | | | | | | |
28 | number of fetuses with cardiovascular malformations to total number of fetuses ratio | WM/Nem | both | 18 | % | trypan blue (60 mg/kg) | 111303 | trypan blue (60 mg/kg) | | | | | | | |
21 | number of fetuses with cardiovascular malformations to total number of fetuses ratio | WM/Nem | both | 8.3 | % | trypan blue (120 mg/kg) | 111304 | trypan blue (120 mg/kg) | | | | | | | |
51 | number of fetuses with cardiovascular malformations to total number of fetuses ratio | BDIX/Nem | both | 2.6 | % | trypan blue (0 mg/kg) | 111305 | trypan blue (0 mg/kg) | | | | | | | |
60 | number of fetuses with cardiovascular malformations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111306 | trypan blue (60 mg/kg) | | | | | | | |
32 | number of fetuses with cardiovascular malformations to total number of fetuses ratio | BDIX/Nem | both | 13.3 | % | trypan blue (120 mg/kg) | 111307 | trypan blue (120 mg/kg) | | | | | | | |
43 | number of fetuses with renal malformations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111308 | trypan blue (0 mg/kg) | | | | | | | |
16 | number of fetuses with renal malformations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (40 mg/kg) | 111309 | trypan blue (40 mg/kg) | | | | | | | |
28 | number of fetuses with renal malformations to total number of fetuses ratio | WM/Nem | both | 5.9 | % | trypan blue (60 mg/kg) | 111310 | trypan blue (60 mg/kg) | | | | | | | |
21 | number of fetuses with renal malformations to total number of fetuses ratio | WM/Nem | both | 8.3 | % | trypan blue (120 mg/kg) | 111311 | trypan blue (120 mg/kg) | | | | | | | |
51 | number of fetuses with renal malformations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111312 | trypan blue (0 mg/kg) | | | | | | | |
60 | number of fetuses with renal malformations to total number of fetuses ratio | BDIX/Nem | both | 2.8 | % | trypan blue (60 mg/kg) | 111313 | trypan blue (60 mg/kg) | | | | | | | |
32 | number of fetuses with renal malformations to total number of fetuses ratio | BDIX/Nem | both | 5.9 | % | trypan blue (120 mg/kg) | 111314 | trypan blue (120 mg/kg) | | | | | | | |
43 | number of fetuses with left umbilical artery to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111315 | trypan blue (0 mg/kg) | | | | | | | |
16 | number of fetuses with left umbilical artery to total number of fetuses ratio | WM/Nem | both | 33.3 | % | trypan blue (40 mg/kg) | 111316 | trypan blue (40 mg/kg) | | | | | | | |
141 | number of fetuses with external malformations to total number of live fetuses ratio | WM/Nem | both | 1.7 | % | trypan blue (0 mg/kg) | 111233 | trypan blue (0 mg/kg) | | | | | | | |
85 | number of fetuses with external malformations to total number of live fetuses ratio | WM/Nem | both | 15.9 | % | trypan blue (30 mg/kg) | 111235 | trypan blue (30 mg/kg) | | | | | | | |
47 | number of fetuses with external malformations to total number of live fetuses ratio | WM/Nem | both | 28.7 | % | trypan blue (40 mg/kg) | 111236 | trypan blue (40 mg/kg) | | | | | | | |
96 | number of fetuses with external malformations to total number of live fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111239 | trypan blue (0 mg/kg) | | | | | | | |
107 | number of fetuses with external malformations to total number of live fetuses ratio | BDIX/Nem | both | 1.3 | % | trypan blue (60 mg/kg) | 111240 | trypan blue (60 mg/kg) | | | | | | | |
73 | number of fetuses with external malformations to total number of live fetuses ratio | BDIX/Nem | both | 10.5 | % | trypan blue (120 mg/kg) | 111241 | trypan blue (120 mg/kg) | | | | | | | |
76 | number of fetuses with exencephaly to total number of live fetuses ratio | WM/Nem | both | 0 | % | trypan blue (20 mg/kg) | 111243 | trypan blue (20 mg/kg) | | | | | | | |
85 | number of fetuses with exencephaly to total number of live fetuses ratio | WM/Nem | both | 8.6 | % | trypan blue (30 mg/kg) | 111244 | trypan blue (30 mg/kg) | | | | | | | |
74 | number of fetuses with exencephaly to total number of live fetuses ratio | WM/Nem | both | 13.9 | % | trypan blue (60 mg/kg) | 111246 | trypan blue (60 mg/kg) | | | | | | | |
50 | number of fetuses with exencephaly to total number of live fetuses ratio | WM/Nem | both | 27 | % | trypan blue (120 mg/kg) | 111247 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses with exencephaly to total number of live fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111248 | trypan blue (0 mg/kg) | | | | | | | |
107 | number of fetuses with exencephaly to total number of live fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111249 | trypan blue (60 mg/kg) | | | | | | | |
76 | number of fetuses with brain hernia to total number of live fetuses ratio | WM/Nem | both | 2 | % | trypan blue (20 mg/kg) | 111252 | trypan blue (20 mg/kg) | | | | | | | |
85 | number of fetuses with brain hernia to total number of live fetuses ratio | WM/Nem | both | 3.7 | % | trypan blue (30 mg/kg) | 111253 | trypan blue (30 mg/kg) | | | | | | | |
74 | number of fetuses with brain hernia to total number of live fetuses ratio | WM/Nem | both | 10.9 | % | trypan blue (60 mg/kg) | 111255 | trypan blue (60 mg/kg) | | | | | | | |
50 | number of fetuses with brain hernia to total number of live fetuses ratio | WM/Nem | both | 23 | % | trypan blue (120 mg/kg) | 111256 | trypan blue (120 mg/kg) | | | | | | | |
73 | number of fetuses with brain hernia to total number of live fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (120 mg/kg) | 111259 | trypan blue (120 mg/kg) | | | | | | | |
12 | number of blastocysts implanted per litter | WM/Nem | both | 12.1 | | trypan blue (60 mg/kg) | 111264 | trypan blue (60 mg/kg) | | | | | | | |
50 | number of fetuses with external malformations to total number of live fetuses ratio | WM/Nem | both | 53.2 | % | trypan blue (120 mg/kg) | 111238 | trypan blue (120 mg/kg) | | | | | | | |
47 | number of fetuses with exencephaly to total number of live fetuses ratio | WM/Nem | both | 15.8 | % | trypan blue (40 mg/kg) | 111245 | trypan blue (40 mg/kg) | | | | | | | |
73 | number of fetuses with exencephaly to total number of live fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (120 mg/kg) | 111250 | trypan blue (120 mg/kg) | | | | | | | |
141 | number of fetuses with brain hernia to total number of live fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111251 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses with brain hernia to total number of live fetuses ratio | WM/Nem | both | 10 | % | trypan blue (40 mg/kg) | 111254 | trypan blue (40 mg/kg) | | | | | | | |
96 | number of fetuses with brain hernia to total number of live fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111257 | trypan blue (0 mg/kg) | | | | | | | |
107 | number of fetuses with brain hernia to total number of live fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111258 | trypan blue (60 mg/kg) | | | | | | | |
13 | number of blastocysts implanted per litter | WM/Nem | both | 12.6 | | control condition | 111260 | control condition | | | | | | | |
11 | number of blastocysts/embryos lost postimplantation to litter size ratio | WM/Nem | both | 58.6 | % | trypan blue (40 mg/kg) | 111272 | trypan blue (40 mg/kg) | | | | | | | |
10 | number of blastocysts/embryos lost postimplantation to litter size ratio | WM/Nem | both | 51.6 | % | trypan blue (120 mg/kg) | 111274 | trypan blue (120 mg/kg) | | | | | | | |
13 | number of blastocysts/embryos lost postimplantation to litter size ratio | BDIX/Nem | both | 21.6 | % | control condition | 111275 | control condition | | | | | | | |
141 | number of fetuses with eye malformations to total number of live fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111278 | trypan blue (0 mg/kg) | | | | | | | |
76 | number of fetuses with eye malformations to total number of live fetuses ratio | WM/Nem | both | 2 | % | trypan blue (20 mg/kg) | 111279 | trypan blue (20 mg/kg) | | | | | | | |
76 | number of fetuses with external malformations to total number of live fetuses ratio | WM/Nem | both | 2 | % | trypan blue (20 mg/kg) | 111234 | trypan blue (20 mg/kg) | | | | | | | |
74 | number of fetuses with external malformations to total number of live fetuses ratio | WM/Nem | both | 45.5 | % | trypan blue (60 mg/kg) | 111237 | trypan blue (60 mg/kg) | | | | | | | |
141 | number of fetuses with exencephaly to total number of live fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111242 | trypan blue (0 mg/kg) | | | | | | | |
12 | number of blastocysts implanted per litter | WM/Nem | both | 12.8 | | trypan blue (30 mg/kg) | 111262 | trypan blue (30 mg/kg) | | | | | | | |
11 | number of blastocysts implanted per litter | WM/Nem | both | 10.5 | | trypan blue (40 mg/kg) | 111263 | trypan blue (40 mg/kg) | | | | | | | |
14 | number of blastocysts implanted per litter | BDIX/Nem | both | 9.4 | | trypan blue (120 mg/kg) | 111268 | trypan blue (120 mg/kg) | | | | | | | |
13 | number of blastocysts/embryos lost postimplantation to litter size ratio | WM/Nem | both | 13 | % | control condition | 111269 | control condition | | | | | | | |
12 | number of blastocysts/embryos lost postimplantation to litter size ratio | WM/Nem | both | 51.5 | % | trypan blue (60 mg/kg) | 111273 | trypan blue (60 mg/kg) | | | | | | | |
107 | number of fetuses with eye malformations to total number of live fetuses ratio | BDIX/Nem | both | 1.3 | % | trypan blue (60 mg/kg) | 111285 | trypan blue (60 mg/kg) | | | | | | | |
10 | number of blastocysts implanted per litter | WM/Nem | both | 12.9 | | trypan blue (120 mg/kg) | 111265 | trypan blue (120 mg/kg) | | | | | | | |
13 | number of blastocysts implanted per litter | BDIX/Nem | both | 9.2 | | control condition | 111266 | control condition | | | | | | | |
16 | number of blastocysts implanted per litter | BDIX/Nem | both | 10.5 | | trypan blue (60 mg/kg) | 111267 | trypan blue (60 mg/kg) | | | | | | | |
10 | number of blastocysts/embryos lost postimplantation to litter size ratio | WM/Nem | both | 33.3 | % | trypan blue (20 mg/kg) | 111270 | trypan blue (20 mg/kg) | | | | | | | |
12 | number of blastocysts/embryos lost postimplantation to litter size ratio | WM/Nem | both | 43.4 | % | trypan blue (30 mg/kg) | 111271 | trypan blue (30 mg/kg) | | | | | | | |
16 | number of blastocysts/embryos lost postimplantation to litter size ratio | BDIX/Nem | both | 34.8 | % | trypan blue (60 mg/kg) | 111276 | trypan blue (60 mg/kg) | | | | | | | |
14 | number of blastocysts/embryos lost postimplantation to litter size ratio | BDIX/Nem | both | 44.9 | % | trypan blue (120 mg/kg) | 111277 | trypan blue (120 mg/kg) | | | | | | | |
85 | number of fetuses with eye malformations to total number of live fetuses ratio | WM/Nem | both | 5.2 | % | trypan blue (30 mg/kg) | 111280 | trypan blue (30 mg/kg) | | | | | | | |
47 | number of fetuses with eye malformations to total number of live fetuses ratio | WM/Nem | both | 0 | % | trypan blue (40 mg/kg) | 111281 | trypan blue (40 mg/kg) | | | | | | | |
74 | number of fetuses with eye malformations to total number of live fetuses ratio | WM/Nem | both | 26.1 | % | trypan blue (60 mg/kg) | 111282 | trypan blue (60 mg/kg) | | | | | | | |
50 | number of fetuses with eye malformations to total number of live fetuses ratio | WM/Nem | both | 19.5 | % | trypan blue (120 mg/kg) | 111283 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses with eye malformations to total number of live fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111284 | trypan blue (0 mg/kg) | | | | | | | |
73 | number of fetuses with eye malformations to total number of live fetuses ratio | BDIX/Nem | both | 9.6 | % | trypan blue (120 mg/kg) | 111286 | trypan blue (120 mg/kg) | | | | | | | |
28 | number of fetuses with left umbilical artery to total number of fetuses ratio | WM/Nem | both | 22 | % | trypan blue (60 mg/kg) | 111317 | trypan blue (60 mg/kg) | | | | | | | |
96 | number of fetuses with skeletal malformations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111322 | trypan blue (0 mg/kg) | | | | | | | |
30 | number of fetuses with skeletal malformations to total number of fetuses ratio | WM/Nem | both | 16 | % | trypan blue (40 mg/kg) | 111323 | trypan blue (40 mg/kg) | | | | | | | |
46 | number of fetuses with skeletal malformations to total number of fetuses ratio | WM/Nem | both | 12.1 | % | trypan blue (60 mg/kg) | 111324 | trypan blue (60 mg/kg) | | | | | | | |
29 | number of fetuses with skeletal malformations to total number of fetuses ratio | WM/Nem | both | 24.1 | % | trypan blue (120 mg/kg) | 111325 | trypan blue (120 mg/kg) | | | | | | | |
45 | number of fetuses with skeletal malformations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111326 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses with skeletal malformations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111327 | trypan blue (60 mg/kg) | | | | | | | |
31 | number of fetuses with skeletal malformations to total number of fetuses ratio | BDIX/Nem | both | 6.7 | % | trypan blue (120 mg/kg) | 111328 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses with cranial malformations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111329 | trypan blue (0 mg/kg) | | | | | | | |
30 | number of fetuses with cranial malformations to total number of fetuses ratio | WM/Nem | both | 7.6 | % | trypan blue (40 mg/kg) | 111330 | trypan blue (40 mg/kg) | | | | | | | |
46 | number of fetuses with cranial malformations to total number of fetuses ratio | WM/Nem | both | 9.4 | % | trypan blue (60 mg/kg) | 111331 | trypan blue (60 mg/kg) | | | | | | | |
29 | number of fetuses with cranial malformations to total number of fetuses ratio | WM/Nem | both | 13.3 | % | trypan blue (120 mg/kg) | 111332 | trypan blue (120 mg/kg) | | | | | | | |
45 | number of fetuses with cranial malformations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111333 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses with cranial malformations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111334 | trypan blue (60 mg/kg) | | | | | | | |
31 | number of fetuses with cranial malformations to total number of fetuses ratio | BDIX/Nem | both | 3.3 | % | trypan blue (120 mg/kg) | 111335 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses with vertebral malformations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111336 | trypan blue (0 mg/kg) | | | | | | | |
30 | number of fetuses with vertebral malformations to total number of fetuses ratio | WM/Nem | both | 8.3 | % | trypan blue (40 mg/kg) | 111337 | trypan blue (40 mg/kg) | | | | | | | |
46 | number of fetuses with vertebral malformations to total number of fetuses ratio | WM/Nem | both | 16.3 | % | trypan blue (60 mg/kg) | 111338 | trypan blue (60 mg/kg) | | | | | | | |
29 | number of fetuses with vertebral malformations to total number of fetuses ratio | WM/Nem | both | 15 | % | trypan blue (120 mg/kg) | 111339 | trypan blue (120 mg/kg) | | | | | | | |
45 | number of fetuses with vertebral malformations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111340 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses with vertebral malformations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111341 | trypan blue (60 mg/kg) | | | | | | | |
31 | number of fetuses with vertebral malformations to total number of fetuses ratio | BDIX/Nem | both | 3.3 | % | trypan blue (120 mg/kg) | 111342 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses with sternum variations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111343 | trypan blue (0 mg/kg) | | | | | | | |
30 | number of fetuses with sternum variations to total number of fetuses ratio | WM/Nem | both | 4.2 | % | trypan blue (40 mg/kg) | 111344 | trypan blue (40 mg/kg) | | | | | | | |
46 | number of fetuses with sternum variations to total number of fetuses ratio | WM/Nem | both | 8.3 | % | trypan blue (60 mg/kg) | 111345 | trypan blue (60 mg/kg) | | | | | | | |
29 | number of fetuses with sternum variations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (120 mg/kg) | 111346 | trypan blue (120 mg/kg) | | | | | | | |
45 | number of fetuses with sternum variations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111347 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses with sternum variations to total number of fetuses ratio | BDIX/Nem | both | 1.7 | % | trypan blue (60 mg/kg) | 111348 | trypan blue (60 mg/kg) | | | | | | | |
31 | number of fetuses with sternum variations to total number of fetuses ratio | BDIX/Nem | both | 10.8 | % | trypan blue (120 mg/kg) | 111349 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses with cervical rib variations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111350 | trypan blue (0 mg/kg) | | | | | | | |
30 | number of fetuses with cervical rib variations to total number of fetuses ratio | WM/Nem | both | 1.4 | % | trypan blue (40 mg/kg) | 111351 | trypan blue (40 mg/kg) | | | | | | | |
46 | number of fetuses with cervical rib variations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111352 | trypan blue (60 mg/kg) | | | | | | | |
29 | number of fetuses with cervical rib variations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (120 mg/kg) | 111353 | trypan blue (120 mg/kg) | | | | | | | |
45 | number of fetuses with cervical rib variations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111354 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses with cervical rib variations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111355 | trypan blue (60 mg/kg) | | | | | | | |
31 | number of fetuses with cervical rib variations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (120 mg/kg) | 111356 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses with lumbar rib variations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111357 | trypan blue (0 mg/kg) | | | | | | | |
30 | number of fetuses with lumbar rib variations to total number of fetuses ratio | WM/Nem | both | 12.5 | % | trypan blue (40 mg/kg) | 111358 | trypan blue (40 mg/kg) | | | | | | | |
46 | number of fetuses with lumbar rib variations to total number of fetuses ratio | WM/Nem | both | 20.8 | % | trypan blue (60 mg/kg) | 111359 | trypan blue (60 mg/kg) | | | | | | | |
29 | number of fetuses with lumbar rib variations to total number of fetuses ratio | WM/Nem | both | 41.7 | % | trypan blue (120 mg/kg) | 111360 | trypan blue (120 mg/kg) | | | | | | | |
45 | number of fetuses with lumbar rib variations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111361 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses with lumbar rib variations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111362 | trypan blue (60 mg/kg) | | | | | | | |
31 | number of fetuses with lumbar rib variations to total number of fetuses ratio | BDIX/Nem | both | 0 | % | trypan blue (120 mg/kg) | 111363 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111364 | trypan blue (0 mg/kg) | | | | | | | |
30 | number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (40 mg/kg) | 111365 | trypan blue (40 mg/kg) | | | | | | | |
46 | number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (60 mg/kg) | 111366 | trypan blue (60 mg/kg) | | | | | | | |
29 | number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (120 mg/kg) | 111367 | trypan blue (120 mg/kg) | | | | | | | |
45 | number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio | BDIX/Nem | both | 44.6 | % | trypan blue (0 mg/kg) | 111368 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio | BDIX/Nem | both | 22.2 | % | trypan blue (60 mg/kg) | 111369 | trypan blue (60 mg/kg) | | | | | | | |
31 | number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratio | BDIX/Nem | both | 28.3 | % | trypan blue (120 mg/kg) | 111370 | trypan blue (120 mg/kg) | | | | | | | |
96 | number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio | WM/Nem | both | 28.7 | % | trypan blue (0 mg/kg) | 111371 | trypan blue (0 mg/kg) | | | | | | | |
30 | number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio | WM/Nem | both | 57.8 | % | trypan blue (40 mg/kg) | 111372 | trypan blue (40 mg/kg) | | | | | | | |
46 | number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio | WM/Nem | both | 67.6 | % | trypan blue (60 mg/kg) | 111373 | trypan blue (60 mg/kg) | | | | | | | |
29 | number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio | WM/Nem | both | 85 | % | trypan blue (120 mg/kg) | 111374 | trypan blue (120 mg/kg) | | | | | | | |
45 | number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio | BDIX/Nem | both | 8.2 | % | trypan blue (0 mg/kg) | 111375 | trypan blue (0 mg/kg) | | | | | | | |
47 | number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio | BDIX/Nem | both | 14.1 | % | trypan blue (60 mg/kg) | 111376 | trypan blue (60 mg/kg) | | | | | | | |
31 | number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratio | BDIX/Nem | both | 51.7 | % | trypan blue (120 mg/kg) | 111377 | trypan blue (120 mg/kg) | | | | | | | |
10 | number of blastocysts implanted per litter | WM/Nem | both | 11.4 | | trypan blue (20 mg/kg) | 111261 | trypan blue (20 mg/kg) | | | | | | | |
43 | number of fetuses with visceral malformations to total number of fetuses ratio | WM/Nem | both | 0 | % | trypan blue (0 mg/kg) | 111287 | trypan blue (0 mg/kg) | | | | | | | |
21 | number of fetuses with left umbilical artery to total number of fetuses ratio | WM/Nem | both | 33.3 | % | trypan blue (120 mg/kg) | 111318 | trypan blue (120 mg/kg) | | | | | | | |
51 | number of fetuses with left umbilical artery to total number of fetuses ratio | BDIX/Nem | both | 1.5 | % | trypan blue (0 mg/kg) | 111319 | trypan blue (0 mg/kg) | | | | | | | |
60 | number of fetuses with left umbilical artery to total number of fetuses ratio | BDIX/Nem | both | 6.8 | % | trypan blue (60 mg/kg) | 111320 | trypan blue (60 mg/kg) | | | | | | | |
32 | number of fetuses with left umbilical artery to total number of fetuses ratio | BDIX/Nem | both | 20.5 | % | trypan blue (120 mg/kg) | 111321 | trypan blue (120 mg/kg) | | | | | | | |
6 | post-insult time of death due to metastatic liver tumors | BDIX/OrlIco | male | 114 | d | PRObR1 cells (2 x 10E6 cells) then phosphate buffered saline (1 ml) (for 7 days) | 107418 | PRObR1 cells (2 x 10E6 cells) | | phosphate buffered saline (1 ml) (for 7 days) | | | | | |
6 | post-insult time of death due to metastatic liver tumors | BDIX/OrlIco | male | 34 | d | PROb cells (2 x 10E6 cells) then phosphate buffered saline (1 ml) (for 7 days) | 107419 | PROb cells (2 x 10E6 cells) | | phosphate buffered saline (1 ml) (for 7 days) | | | | | |
6 | post-insult time of death due to metastatic liver tumors | BDIX/OrlIco | male | 66 | d | PROb cells (2 x 10E6 cells) then sodium butyrate (20 mmol/l) (for 7 days) and interleukin-2 (45 x 10E4 IU/kg) (for 5 days) | 107420 | PROb cells (2 x 10E6 cells) | | sodium butyrate (20 mmol/l) (for 7 days) | interleukin-2 (45 x 10E4 IU/kg) (for 5 days) | | | | |
16 | metastatic intraperitoneal tumor weight | WAG/OlaHsd | male | 7.42 | g | CC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days) | 107874 | CC531 cells (5 X 10E6) (for 21 days) | | vehicle control condition (1 ml) (for 21 days) | | | | | |
16 | metastatic intraperitoneal tumor weight | WAG/OlaHsd | male | 3.22 | g | CC531 cells (5 X 10E6) (for 21 days) then phosphoramidon (250 mg) (for 21 days) | 107875 | CC531 cells (5 X 10E6) (for 21 days) | | phosphoramidon (250 mg) (for 21 days) | | | | | |
N/A | percentage of study population developing meconium ileus during a period of time | SD-Cftrem2Apb | not specified | 40 | % | controlled ColonLYTELY content drinking water (4.5 %) (for 7 days) | 111464 | controlled ColonLYTELY content drinking water (4.5 %) (for 7 days) | | | | | | | |
N/A | percentage of study population developing meconium ileus during a period of time | SD-Cftrem1Apb | not specified | 16 | % | control condition | 111463 | control condition | | | | | | | |